Login Get Started
Browse Breadcrumb chevron Shares Breadcrumb chevron Healthcare Breadcrumb chevron Biotechnology & Medical Research Breadcrumb chevron Oyster Point Pharma Inc
Oyster Point Pharma Inc logo

OYST - Oyster Point Pharma Inc Share News

$21.35 0.2  0.8%

Last Trade - 15/04/21

Sector
Healthcare
RiskRating
Adventurous
Size
Mid Cap
Style
Sucker Stock
Market Cap £398.5m
Enterprise Value £258.7m
Revenue £n/a
Position in Universe 3424th / 6854
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions OYST Dividends
All News
All News Reuters News Company Announcements
BRIEF-Oyster Point Pharma Announces New Appointment To Board Of Directors
5th Apr News
Oyster Point Pharma Announces New Appointment to Board of Directors
5th Apr News
BRIEF-Oyster Point Pharma Announces FDA Acceptance For Filing New Drug Application For OC-01 Nasal Spray For Treatment Of Signs And Symptoms Of Dry Eye Disease
2nd Mar News
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
2nd Mar News
Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
25th Feb News
BRIEF-Oyster Point Pharma Reports Q4 Loss Per Share $0.86
18th Feb News
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
18th Feb News
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
12th Feb News
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
29th Dec '20 News
BRIEF-Oyster Point Files Prospectus Supplement Related To Common Stock Offering Of Up To $100 Million
18th Dec '20 News
BRIEF-Oyster Point Pharma Submits New Drug Application To The U.S. Food And Drug Administration For OC-01 (Varenicline)
18th Dec '20 News
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
18th Dec '20 News
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
7th Dec '20 News
BRIEF-Oyster Point Pharma Submits Phase 2 Clinical Trial Protocol To Evaluate OC-01 Nasal Spray For Neurotrophic Keratitis
1st Dec '20 News
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
1st Dec '20 News
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
25th Nov '20 News
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
13th Nov '20 News
BRIEF-Oyster Point Pharma Inc Files For Mixed Shelf Of Upto $300 Million
5th Nov '20 News
BRIEF-Oyster Point Pharma Reports Third Quarter 2020 Financial Results And Recent Business Highlights
5th Nov '20 News
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
5th Nov '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.